Compounds > indazoles
Page last updated: 2024-08-21

indazoles and Angiosarcoma

indazoles has been researched along with Angiosarcoma in 25 studies

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's17 (68.00)24.3611
2020's8 (32.00)2.80

Authors

AuthorsStudies
Adams, B; Attia, S; Brohl, AS; Burgess, MA; Chawla, S; Cheang, MCU; Cranmer, LD; Ganjoo, KN; Italiano, A; Jones, RL; Liu, L; Maki, RG; Ravi, V; Robertson, L; Theuer, C; Thornton, K1
Agulnik, M; Kraft, AS; Litwin, S; Movva, S; Ravi, V; Schuetze, SM; Somaiah, N; Tetzlaff, ED; Thiebaud, JA; von Mehren, M1
Browne, LP; Cost, CR; Galambos, C; Knight-Perry, J; Koo, J1
Agostinetto, E; D'Amico, T; De Sanctis, R; Lorenzi, E; Santoro, A; Simonelli, M1
Hayashi, M; Makino, T; Mizawa, M; Mori, N; Shimizu, T1
Fujiwara, S; Nakamura, K; Nakano, E; Nishigori, C; Ogura, K; Washio, K1
Iwaki, Y; Kamo, R; Nakai, K; Ozawa, T; Tsuruta, D; Watanabe, M1
Maeda, T; Nakano, E; Namikawa, K; Oashi, K; Shibata, T; Takahashi, A; Teramoto, Y; Tsutsumida, A; Yamazaki, N; Yokota, K1
Keam, B; Kim, DW; Kim, M; Kim, SH; Kim, TM; Kim, YJ; Kwak, Y; Moon, KC; Park, C1
Benson, C; Freivogel, KW; Gelderblom, H; Grignani, G; Jobanputra, M; Judson, IR; Katz, D; Manson, SC; Merimsky, O; Mungul, A; Sanfilippo, R; Stein, D1
Chen, H; Jia, J; Li, X; Liu, D; Liu, L; Ma, J; Qiao, Y; Wang, W; Wang, Y; Wu, P; Xi, H; Yang, J; Zeng, Y; Zhang, L; Zhao, Y1
Chen, WJ; Wu, CC; Wu, IC; Yu, FJ1
Liu, L; Mehta, CR; Theuer, C1
Hasunuma, N; Manabe, M; Osada, SI; Toyoshima, A; Yamada, K; Yamada, M1
Hata, H; Imafuku, K; Kitamura, S; Maeda, T; Masuzawa, M; Shimizu, H; Yanagi, T1
Abe, K; Asai, M; Koike, Y; Ogawa, F; Tanioka, M; Tomita, H; Utani, A1
Brown, NJ; Reed, MW; Staton, CA; Woll, PJ; Young, RJ1
Miura, H; Shirai, H1
Haga, N; Hata, H; Homma, E; Imafuku, K; Kitamura, S; Shimizu, H1
Ali, SM; Futreal, A; Miller, VA; Patel, S; Ramesh, N; Ravi, V; Ross, JS; Sanford, EM; Stephens, PJ; Wang, WL1
Hata, H; Imafuku, K; Inamura, Y; Kitamura, S; Shimizu, H; Yanagi, T; Yoshino, K1
Oashi, K; Ogata, D; Suzuki, K; Tsuchida, T; Yamazaki, N; Yanagisawa, H1
Hirabayashi, M; Hoashi, T; Nakajima, R; Saeki, H; Takahashi, N1
Duffaud, F; Gelderblom, H; Grignani, G; Gronchi, A; Guida, M; Jones, RL; Kasper, B; Katz, D; Kollár, A; Litière, S; Marreaud, S; Safwat, A; Sleijfer, S; Stacchiotti, S; Steeghs, N; Touati, N; van der Graaf, WT1
Backes, M; Bode-Erdmann, S; Greulich, S; Hebart, H; Kaufmann, M; Mahrholdt, H; Ong, P; Ott, G; Schumm, J1

Reviews

1 review(s) available for indazoles and Angiosarcoma

ArticleYear
Pediatric Metastatic Cardiac Angiosarcoma Successfully Treated With Multimodal Therapy: Case Report and Review of Literature.
    Journal of pediatric hematology/oncology, 2021, 03-01, Volume: 43, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy; Child; Combined Modality Therapy; Heart Neoplasms; Hemangiosarcoma; Humans; Indazoles; Male; Neoplasms, Second Primary; Prognosis; Pyrimidines; Sulfonamides; Surgical Procedures, Operative

2021

Trials

4 trial(s) available for indazoles and Angiosarcoma

ArticleYear
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial.
    JAMA oncology, 2022, 05-01, Volume: 8, Issue:5

    Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Hemangiosarcoma; Humans; Indazoles; Male; Pyrimidines; Sulfonamides

2022
OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma.
    Cancer, 2022, 10-01, Volume: 128, Issue:19

    Topics: Hemangiosarcoma; Humans; Indazoles; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome; Vascular Endothelial Growth Factor A

2022
An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 01-01, Volume: 30, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Epidemiologic Research Design; Follow-Up Studies; Hemangiosarcoma; Humans; Indazoles; Patient Selection; Prognosis; Pyrimidines; Sulfonamides; Survival Rate

2019
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
    Acta oncologica (Stockholm, Sweden), 2017, Volume: 56, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Follow-Up Studies; Hemangioendothelioma, Epithelioid; Hemangiosarcoma; Humans; Indazoles; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neoplasms; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Rate; Tunica Intima

2017

Other Studies

20 other study(ies) available for indazoles and Angiosarcoma

ArticleYear
Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient: A CARE-compliant case report.
    Medicine, 2019, Volume: 98, Issue:50

    Topics: Adolescent; Breast Neoplasms; Combined Modality Therapy; Endosonography; Female; Hemangiosarcoma; Humans; Indazoles; Mastectomy; Primary Ovarian Insufficiency; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Vagina

2019
Effectiveness of pazopanib for local and lung metastases in Stewart-Treves syndrome.
    European journal of dermatology : EJD, 2020, Feb-01, Volume: 30, Issue:1

    Topics: Aged; Angiogenesis Inhibitors; Duodenal Ulcer; Fatal Outcome; Female; Gastrointestinal Hemorrhage; Hemangiosarcoma; Humans; Indazoles; Lung Neoplasms; Lymphangiosarcoma; Pyrimidines; Stomach Ulcer; Sulfonamides

2020
Pazopanib as a potential chemotherapy for cutaneous angiosarcoma: A case series of 10 patients from a single institution.
    The Journal of dermatology, 2020, Volume: 47, Issue:7

    Topics: Hemangiosarcoma; Humans; Indazoles; Pyrimidines; Skin Neoplasms; Sulfonamides

2020
Successful long-term treatment with pazopanib after prior interleukin-2 therapy in patients with metastatic cutaneous angiosarcoma of the scalp.
    Dermatologic therapy, 2020, Volume: 33, Issue:6

    Topics: Hemangiosarcoma; Humans; Indazoles; Interleukin-2; Pyrimidines; Scalp; Skin Neoplasms; Sulfonamides

2020
A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol).
    BMC cancer, 2020, Jul-13, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hemangiosarcoma; Humans; Indazoles; Male; Middle Aged; Paclitaxel; Prognosis; Pyrimidines; Research Design; Salvage Therapy; Skin Neoplasms; Sulfonamides; Young Adult

2020
Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment.
    Cancer research and treatment, 2021, Volume: 53, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Hemangiosarcoma; Humans; Indazoles; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Pyrimidines; Retrospective Studies; Skin Neoplasms; Sulfonamides; Survival Rate

2021
Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study
    Acta oncologica (Stockholm, Sweden), 2017, Volume: 56, Issue:12

    Topics: Angiogenesis Inhibitors; Compassionate Use Trials; Disease-Free Survival; Female; Hemangiosarcoma; Humans; Indazoles; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Pyrimidines; Retrospective Studies; Sarcoma; Sarcoma, Synovial; Solitary Fibrous Tumors; Sulfonamides; Survival Rate; Time Factors; Uterine Neoplasms

2017
Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report.
    BMC cancer, 2018, 02-21, Volume: 18, Issue:1

    Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cell Line, Tumor; Combined Modality Therapy; Hemangiosarcoma; Humans; Immunohistochemistry; Immunotherapy, Adoptive; Indazoles; Liver Neoplasms; Magnetic Resonance Imaging; Male; Neoplasm Metastasis; Neoplasm Staging; Programmed Cell Death 1 Receptor; Pyrimidines; Sulfonamides; Treatment Outcome

2018
Peritoneal epithelioid angiosarcoma: A case report.
    Medicine, 2018, Volume: 97, Issue:38

    Topics: Ascites; Hemangiosarcoma; Humans; Hypotension; Indazoles; Male; Middle Aged; Peritoneal Neoplasms; Postoperative Complications; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Tomography, X-Ray Computed

2018
Prevention of tumor progression in Stewart-Treves syndrome with a low dose of pazopanib.
    The Journal of dermatology, 2019, Volume: 46, Issue:7

    Topics: Aged; Amputation Stumps; Amputation, Surgical; Biopsy; Chemoradiotherapy; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemangiosarcoma; Humans; Indazoles; Leg; Lymphangiosarcoma; Neoplasm Recurrence, Local; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Skin; Skin Neoplasms; Sulfonamides

2019
Evaluation of pazopanib cytotoxicity to normal vascular endothelial cells in vitro: A comment on Goto et al.
    The Journal of dermatology, 2019, Volume: 46, Issue:9

    Topics: Angiogenesis Inhibitors; Apoptosis; Cell Line, Tumor; Cell Survival; Dermis; Endothelium, Vascular; Fibroblasts; Hemangiosarcoma; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Pyrimidines; Skin Neoplasms; Sulfonamides; Toxicity Tests

2019
Angiosarcoma of the scalp successfully treated with pazopanib.
    Journal of the American Academy of Dermatology, 2014, Volume: 70, Issue:1

    Topics: Angiogenesis Inhibitors; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Scalp; Skin Neoplasms; Sulfonamides

2014
Vascular-targeted agents for the treatment of angiosarcoma.
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Axitinib; Bevacizumab; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Movement; Doxorubicin; Everolimus; Hemangiosarcoma; Humans; Imidazoles; Indazoles; Neovascularization, Pathologic; Paclitaxel; Protein Array Analysis; Sirolimus; Vascular Endothelial Growth Factor A

2014
Low-dose administration of oral pazopanib for the treatment of recurrent angiosarcoma.
    Clinical and experimental dermatology, 2015, Volume: 40, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Hemangiosarcoma; Humans; Indazoles; Male; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrimidines; Skin Neoplasms; Sulfonamides; Treatment Outcome

2015
Pazopanib can preserve cosmetic quality of life even in end-stage angiosarcoma.
    Clinical and experimental dermatology, 2015, Volume: 40, Issue:8

    Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Indazoles; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Scalp; Skin Neoplasms; Sulfonamides

2015
Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2016, Volume: 14, Issue:5

    Topics: Aged, 80 and over; Angiogenesis Inhibitors; Hemangiosarcoma; Humans; Indazoles; Male; Pyrimidines; Signal Transduction; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2

2016
Pazopanib does not bring remarkable improvement in patients with angiosarcoma.
    The Journal of dermatology, 2017, Volume: 44, Issue:1

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Chemical and Drug Induced Liver Injury; Disease-Free Survival; Fatigue; Female; Hemangiosarcoma; Humans; Indazoles; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Sulfonamides; Thrombocytopenia; Treatment Outcome

2017
Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma.
    Medical oncology (Northwood, London, England), 2016, Volume: 33, Issue:10

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bridged-Ring Compounds; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hemangiosarcoma; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Retrospective Studies; Skin Neoplasms; Sulfonamides; Taxoids

2016
Paradoxical antitumor effects of pazopanib in a cutaneous angiosarcoma patient.
    The Journal of dermatology, 2017, Volume: 44, Issue:9

    Topics: Aged; Angiogenesis Inhibitors; Disease Progression; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Indazoles; Male; Pyrimidines; Skin Neoplasms; Sulfonamides

2017
Favorable course of pericardial angiosarcoma under paclitaxel followed by pazopanib treatment documented by cardiovascular magnetic resonance imaging.
    Circulation, 2012, Oct-30, Volume: 126, Issue:18

    Topics: Adrenal Cortex Hormones; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Delayed Diagnosis; Diagnostic Errors; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Heart Neoplasms; Hemangiosarcoma; Humans; Ifosfamide; Indazoles; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Myocardium; Paclitaxel; Pericardial Effusion; Pericardiocentesis; Pericarditis; Pericardium; Protein Kinase Inhibitors; Pulmonary Embolism; Pyrimidines; Remission Induction; Sulfonamides; Vincristine

2012